Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model

Cancer

Volumn 116, Issue 7, 2010, Pages 1739-1750

  Xu, Xiaoyu ^a   Prestwich, Glenn D ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Antiangiogenesis; Autotaxin inhibitor; Engineered tumor xenograft; Extracel; Hyaluronic acid; Injectable hydrogel; LPA antagonist; Lysophospholipid signaling

Indexed keywords

AUTOTAXIN; ENZYME INHIBITOR; GLYCOSAMINOGLYCAN; GROWTH FACTOR; LAMININ; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID ANTAGONIST; LYSOPHOSPHOLIPASE; LYSOPHOSPHOLIPASE D; MATRIGEL; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENCAPSULATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; VASCULARIZATION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; EXTRACELLULAR MATRIX; FEMALE; HUMANS; HYDROGEL; LAMININ; LUNG NEOPLASMS; LYSOPHOSPHOLIPIDS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; RECEPTORS, LYSOPHOSPHATIDIC ACID; TISSUE ENGINEERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950254571     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24907     Document Type: Article

References (62)

1. Giaccone G. The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res. 2007;13:1961-1970.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379-392.
4. Tu M, Xu L, Wei X, Miao Y. How to establish a solitary and localized VX2 lung cancer rabbit model? A simple and effective intrapulmonary tumor implantation technique. J Surg Res. 2009;154:284-292.
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
6. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006;66:3351-3354.
7. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther. 2003;2(4 suppl 1):S134-139.
8. Marx J. Building better mouse models for studying cancer. Science. 2003;299:1972-1975.
9. McLemore TL, Liu MC, Blacker PC, et al. Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res. 1987;47:5132-5140.
10. Gazdar AF, Carney DN, Sims HL, Simmons A. Heterotransplantation of small-cell carcinoma of the lung into nude mice: comparison of intracranial and subcutaneous routes. Int J Cancer. 1981;28:777-783.
11. Kleinman H, McGarvey M, Hassell J, et al. Basement membrane complexes with biological activity. Biochemistry. 1986;25:312-318.
12. Prestwich GD. Evaluating drug efficacy and toxicology in 3 dimensions: using synthetic extracellular matrices in drug discovery. Acc Chem Res. 2008;41:139-148.
13. Shu XZ, Ahmad S, Liu Y, Prestwich GD. Synthesis and evaluation of injectable, in situ crosslinkable synthetic extracellular matrices for tissue engineering. J Biomed Mater Res A. 2006;79:902-912.
14. Liu Y, Shu XZ, Prestwich GD. Tumor engineering: Orthotopic cancer models in mice using cell-loaded, injectable, cross-linked hyaluronan derived hydrogels. Tissue Eng. 2007;13:1091-1101.
15. Scaife CL, Shea JE, Dai Q, Firpo MA, Prestwich GD, Mulvihill SJ. Synthetic extracellular matrix enhances tumor growth and metastasis in an orthotopic mouse model of pancreatic adenocarcinoma. J Gastrointest Surg. 2008;12:1074-1080.
16. Zhang H, Xu X, Gajewiak J, et al. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009;69:5441-5449.
17. Goudar RK, Vlahovic G. Hypoxia, angiogenesis, and lung cancer. Curr Oncol Rep. 2008;10:277-282.
18. Sasaki T, Tanno S, Shibukawa K, Osanai S, Kawabe J, Ohsaki Y. Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts. Int J Oncol. 2008;33:525-532.
19. Cai S, Liu Y, Shu XZ, Prestwich GD. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials. 2005;26:6054-6067.
20. Peattie RA, Yu B, Cai S, et al. Effect of gelatin on heparin regulation of cytokine release from hyaluronan-based hydrogels. Drug Delivery. 2008;15:363-371.
21. Pike DB, Cai S, Pomraning KR, et al. Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials. 2006;27:5242-5251.
22. Riley CM, Fuegy PW, Firpo MA, Shu XZ, Prestwich GD, Peattie RA. Stimulation of in vivo angiogenesis using dual growth factor-loaded crosslinked glycosaminoglycan hydrogels. Biomaterials. 2006;27:5935-5943.
23. Hosack L, Firpo MA, Scott JA, Prestwich GD, Peattie RA. Microvascular maturity elicited in tissue treated with cytokine-loaded hyaluronan-based hydrogels. Biomaterials. 2008;29:2336-2347.
24. Zhao J, Zhang N, Scott JA, Prestwich GD, Wen X. Recruitment of endogenous stem cells for tissue repair. Macromol Biosci. 2008;8:836-842.
25. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 2003;3:582-591.
26. Anliker B, Chun J. Lysophospholipid G protein-coupled receptors. J Biol Chem. 2004;279:20555-20558.
27. Moolenaar WH, van Meeteren LA, Giepmans BN. The ins and outs of lysophosphatidic acid signaling. Bioessays. 2004;26:870-881.
28. Folkman J. A new link in ovarian cancer angiogenesis: lysophosphatidic acid and vascular endothelial growth factor expression. J Natl Cancer Inst. 2001;93:734-735.
29. Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang X. Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clin Cancer Res. 2009;15:492-501.
30. Murph MM, Hurst-Kennedy J, Newton V, Brindley DN, Radhakrishna H. Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells. Mol Cancer Res. 2007;5:1201-1211.
31. Umezu-Goto M, Tanyi J, Lahad J, et al. Lysophosphatidic acid production and action: validated targets in cancer? J Cellular Biochem. 2004;92:1115-1140.
32. van Meeteren L, Moolenaar W. Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res. 2007;46: 145-160.
33. Tokumura A. Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids. Biochim Biophys Acta 1582(1-3):18-25, 2002.
34. Aoki J, Taira A, Takanezawa Y, et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem. 2002;277:48737-48744.
35. Nam S, Clair T, Campo C, Lee H, Liotta L, Stracke M. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene. 2000;19:241-247.
36. Tanaka M, Okudaira S, Kishi Y, et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem. 2006;281:25822-25830.
37. Jiang G, Xu Y, Fujiwara Y, et al. Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem. 2007;2:679-690.
38. Prestwich GD, Gajewiak J, Zhang H, Yang G, Serban MA. Phosphatase-resistant analogues of lysophosphatidic acid: Agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim Biophys Acta. 2008;1781:588-594.
39. Shu XZ, Ghosh K, Liu Y, et al. Attachment and spreading of fibroblasts on an RGD peptide-modified injectable hyaluronan hydrogel. J Biomed Mat Res. 2004;68A:365-375.
40. Denker SP, Barber DL. Cell migration requires both ion translocation and cytoskeletal anchoring by the Na-H exchanger NHE1. J Cell Biol. 2002;159:1087-1096.
41. Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D, Rao JS. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 1993;53:4143-4147.
42. Hama K, Aoki J, Fukaya M, et al. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem. 2004;279:17634-17639.
43. Jackson T, Chougule MB, Ichite N, Patlolla RR, Singh M. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol. 2008;63:117-126.
44. Terranova VP, Liotta LA, Russo RG, Martin GR. Role of laminin in the attachment and metastasis of murine tumor cells. Cancer Res. 1982;42:2265-3229
45. Terranova VP, Williams JE, Liotta LA, Martin GR. Modulation of the metastatic activity of melanoma cells by laminin and fibronectin. Science. 1984;226:982-985.
46. Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem. 1986;55:1037-1057.
47. Turpeenniemi-Hujanen T, Thorgeirsson UP, Rao CN, Liotta LA. Laminin increases the release of type IV collagenase from malignant cells. J Biol Chem. 1986;261:1883-1889.
48. McCarthy JB, Palm SL, Furcht LT. Migration by haptotaxis of a Schwann cell tumor line to the basement membrane glycoprotein laminin. J Cell Biol. 1983;97:772-777.
49. McCarthy JB, Furcht LT. Laminin and fibronectin promote the haptotactic migration of B16 mouse melanoma cells in vitro. J Cell Biol. 1984;98:1474-1780.
50. Cuikerman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science. 2001;294:1708-1712.
51. Petersen O, Ronnov-Jessen L, Howlett A, Bissell M. Interaction with basement membrance serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA. 1992;89:9064-9068.
52. Schmeichel K, Bissell M. Modeling tissue-specific signaling and organ function in 3 dimensions. J Cell Sci. 2003;116:2377-2388.
53. Debnath J, Brugge J. Modelling glandular epithelial cancers in 3-dimensional cultures. Nature Rev Cancer. 2005;5:675-688.
54. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000;6:2053-2063.
55. Sutherland TE, Schuliga M, Harris T, et al. 2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer. Clin Cancer Res. 2005;11:1722-1732.
56. Teicher BA, Chen V, Shih C, et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res. 2000;6:1016-1023.
57. Ghosh K, Pan Z, Guan E, et al. Cell adaptation to a physiologically relevant ECM mimic with different viscoelastic properties. Biomaterials. 2007;28:671-679.
58. Tashiro K, Sephel GC, Weeks B, et al. A synthetic peptide containing the IKVAV sequence from the A chain of laminin mediates cell attachment, migration, and neurite outgrowth. J Biol Chem. 1989;264:16174-16182.
59. Federico L, Pamuklar Z, Smyth S, Morris A. Therapeutic potential of autotaxin/lysophospholipase D inhibitors. Curr Drug Targets. 2008;9:698-708.
60. van Meeteren LA, Ruurs P, Christodoulou E, et al. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem. 2005;280:21155-21161.
61. Baker D, Fujiwara Y, Pigg KR, Tsukahara R, Kobayashi S, Murofushi H, et al. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem. 2006;281:22786-22793.
62. Saunders L, Ouellette A, Bandle R, et al. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol Cancer Ther. 2008;7:3352-3362.